ATE503756T1 - Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren - Google Patents

Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren

Info

Publication number
ATE503756T1
ATE503756T1 AT06779578T AT06779578T ATE503756T1 AT E503756 T1 ATE503756 T1 AT E503756T1 AT 06779578 T AT06779578 T AT 06779578T AT 06779578 T AT06779578 T AT 06779578T AT E503756 T1 ATE503756 T1 AT E503756T1
Authority
AT
Austria
Prior art keywords
methyl
compounds
nr15b
6alkyl
het
Prior art date
Application number
AT06779578T
Other languages
English (en)
Inventor
Christopher Edlin
Stuart Holman
Paul Jones
Suzanne KEELING
Mika Lindvall
Charlotte Mitchell
Naimisha Trivedi
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE503756T1 publication Critical patent/ATE503756T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06779578T 2005-09-29 2006-09-29 Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren ATE503756T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72159705P 2005-09-29 2005-09-29
PCT/GB2006/003626 WO2007036733A1 (en) 2005-09-29 2006-09-29 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors

Publications (1)

Publication Number Publication Date
ATE503756T1 true ATE503756T1 (de) 2011-04-15

Family

ID=37685723

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06779578T ATE503756T1 (de) 2005-09-29 2006-09-29 Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren

Country Status (7)

Country Link
US (2) US20080255186A1 (de)
EP (2) EP1940836A1 (de)
JP (2) JP5323484B2 (de)
AT (1) ATE503756T1 (de)
DE (1) DE602006021044D1 (de)
ES (1) ES2363795T3 (de)
WO (2) WO2007036734A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940836A1 (de) * 2005-09-29 2008-07-09 Glaxo Group Limited Pyrazolo[3,4-b]pyridinverbindung und deren verwendung als pde4-inhibitor
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds
PT2046787E (pt) * 2006-08-01 2011-06-15 Glaxo Group Ltd Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
NZ579645A (en) * 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
CN101687810A (zh) 2007-04-26 2010-03-31 武田药品工业株式会社 双环化合物及其药物用途
EP2249830A4 (de) * 2008-02-06 2012-07-18 Glaxo Group Ltd Duale pharmakophoren pde4-muscarinische antagonisten
WO2009100169A1 (en) * 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
JP2012502977A (ja) * 2008-09-19 2012-02-02 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼ阻害薬
EP2376481B1 (de) 2009-01-13 2013-08-07 Glaxo Group Limited Pyrimidinecarboxamidderivate als syk-kinasehemmer
CA2793299A1 (en) * 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylquinazolines
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
WO2012061926A1 (en) * 2010-11-08 2012-05-18 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
EP2574607A1 (de) * 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE 10-Modulatoren
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
WO2014172044A1 (en) * 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
DE102014009164A1 (de) * 2014-06-03 2015-12-03 Herbalist & Doc Gesundheitsgesellschaft Mbh Silikonölhaltige nasal anzuwendende Formulierungen
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
EP3377482B1 (de) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulatoren von ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
BR112019012322A2 (pt) 2016-12-20 2019-11-19 Syngenta Participations Ag n-ciclobutil-tiazol-5-carboxamidas com atividade nematicida
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
AR112461A1 (es) 2017-07-24 2019-10-30 Vitae Pharmaceuticals Inc PROCESOS PARA LA PRODUCCIÓN DE SALES Y FORMAS CRISTALINAS DE INHIBIDORES DE RORg
AR112346A1 (es) * 2017-08-10 2019-10-16 Lilly Co Eli Derivados de [1,2,4]triazolo
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883634A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
EP4309722A2 (de) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Einnehmbare vorrichtung zur abgabe eines therapeutischen mittels an den magen-darm-trakt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024728A2 (en) * 2002-09-16 2004-03-25 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
EP1940836A1 (de) * 2005-09-29 2008-07-09 Glaxo Group Limited Pyrazolo[3,4-b]pyridinverbindung und deren verwendung als pde4-inhibitor

Also Published As

Publication number Publication date
DE602006021044D1 (de) 2011-05-12
US20080255186A1 (en) 2008-10-16
EP1940836A1 (de) 2008-07-09
EP1940835B1 (de) 2011-03-30
JP2009510044A (ja) 2009-03-12
EP1940835A1 (de) 2008-07-09
JP5323484B2 (ja) 2013-10-23
WO2007036734A1 (en) 2007-04-05
JP2009510043A (ja) 2009-03-12
ES2363795T3 (es) 2011-08-16
US20090131431A1 (en) 2009-05-21
WO2007036733A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
ATE503756T1 (de) Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
GT200600283A (es) COMPUESTOS DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA LA MODULACIÓN DE LA beta-SECRETASA
RS52216B (en) UNITS AND METHODS FOR FXR MODULATION
RS52009B (en) FUNGICID MIXTURES
ATE376833T1 (de) Chinazolinon-derivate als vanilloid-antagonisten
WO2007109456A3 (en) Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists
RS53599B1 (en) PIRIDON DERIVATIVES FOR STRESS MODULATION OF ACTIVATED PROTEIN KINASE SYSTEMS
EA200870409A1 (ru) Антагонисты киназы pi3
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
DE60327443D1 (de) Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf)
TW200744994A (en) Insecticidal 3-acylaminobenzanilides
PE20120814A1 (es) Compuestos y composiciones como inhibidores de la proteina cinasa
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
MY148380A (en) Insecticidal isoxazolines
RS53061B (en) INHIBITORI PROTEIN KINAZE
PE20060664A1 (es) Amidas biciclicas como inhibidores de cinasa
NI200900032A (es) Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3
ATE450258T1 (de) Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)
PE20140226A1 (es) Compuestos de triazolopiridina
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
WO2008053044A3 (de) Hetarylcarbonsäure-n-(biphen-2-yl)amid-verbindungen
DK1742950T3 (da) Pyrazolo-[4,3-D]-pyrimidiner
EA201001348A1 (ru) Пирролопиримидинкарбоксамиды
EA201000612A1 (ru) Антагонисты cgrp-пептиды

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties